Dasiglucagon

Dasiglucagon is a prescription medication used for the treatment of hypoglycemia.

• Dasiglucagon is available under various brand names: Zegalogue

Common side effects of Dasiglucagon include:

• nausea, vomiting, diarrhea;
• headache;
• pain where an injection was given.

Serious side effects of Dasiglucagon include:

• hives; 
• feeling light-headed; 
• difficulty breathing; 
• fast or slow heartbeat; 
• swelling of the face, lips, tongue, or throat
• severe headache, blurred vision, pounding in the neck or ears; or
• new or ongoing low blood sugar--headache, hunger, sweating, irritability, dizziness, fast heart rate, and feeling anxious or shaky.

Rare side effects of Dasiglucagon include:

• none

Seek medical care or call 911 at once if you have the following serious side effects:

• Severe headache, confusion, slurred speech, arm or leg weakness, trouble walking, loss of coordination, feeling unsteady, very stiff muscles, high fever, profuse sweating, or tremors;
• Serious eye symptoms such as sudden vision loss, blurred vision, tunnel vision, eye pain or swelling, or seeing halos around lights;
• Serious heart symptoms include fast, irregular, or pounding heartbeats; fluttering in the chest; shortness of breath; sudden dizziness, lightheadedness, or passing out.

This is not a complete list of side effects and other serious side effects or health problems that may occur because of the use of this drug. Call your doctor for medical advice about serious side effects or adverse reactions. You may report side effects or health problems to FDA at 1-800-FDA-1088.

Adult and pediatric dosage

Injection, solution

• 0.6 mg/0.6 mL single-dose autoinjector or prefilled syringe

Hypoglycemia

Adult dosage

• 0.6 mg SC; if no response after 15 minutes, an additional 0.6-mg dose from a new device may be administered

Pediatric dosage

• Aged below 6 years: Safety and efficacy not established
• Aged above 6 years: 0.6 mg SC; if no response after 15 minutes, an additional 0.6 mg dose from a new device may be administered

Dosage Considerations – Should be Given as Follows: 

• See “Dosages”

If your medical doctor is using this medicine to treat your pain, your doctor or pharmacist may already be aware of any possible drug interactions and may be monitoring you for them. Do not start, stop, or change the dosage of any medicine before checking with your doctor, health care provider, or pharmacist first.

• Dasiglucagon has severe interactions with no other drugs.
• Dasiglucagon has serious interactions with no other drugs.
• Dasiglucagon has moderate interactions with at least 15 other drugs.
• Dasiglucagon has minor interactions with no other drugs.

This information does not contain all possible interactions or adverse effects. Visit the RxList Drug Interaction Checker for any drug interactions. Therefore, before using this product, tell your doctor or pharmacist about all your products. Keep a list of all your medications with you and share this information with your doctor and pharmacist. Check with your healthcare professional or doctor for additional medical advice, or if you have health questions or concerns.

Contraindications

• Pheochromocytoma
• Insulinoma

Effects of drug abuse

• None

Short-Term Effects

• See “What Are Side Effects Associated with Using Dasiglucagon?”

Long-Term Effects

• See “What Are Side Effects Associated with Using Dasiglucagon?”

Cautions

• Contraindicated with pheochromocytoma; glucagon may stimulate catecholamine release from the tumor; if substantial increase in blood pressure develops, phentolamine mesylate 5-10 mg IV has been shown to be effective in lowering blood pressure
• Generalized allergic reactions, including urticaria, respiratory distress, hypotension, and in some cases anaphylactic shock, reported with glucagon products; if symptoms occur, discontinue and treat as indicated
• Treatment for hypoglycemia only effective if sufficient hepatic glycogen present; patients in states of starvation, with adrenal insufficiency, or chronic hypoglycemia may not have adequate levels of hepatic glycogen for therapy to be effective; treat these conditions with glucose
• Insulinoma
• Contraindicated with insulinoma
  • Glucagon may initially produce increased glucose; however, administration may directly or indirectly (via initial rise in blood glucose) stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia
  • If hypoglycemia develops following administration, give PO or IV glucose
• Drug interaction overview
  • Beta-blockers
    • Use with caution
    • Beta-blockers may cause transient increases in pulse and blood pressure
  • Indomethacin
    • Use with caution
    • When used with indomethacin, glucagon may lose its ability to raise blood glucose or may even produce hypoglycemia
  • Warfarin
    • Use with caution
    • Glucagon may increase anticoagulant effect of warfarin

Pregnancy & Lactation

• There are no available data on use in pregnant females to evaluate for drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes
• Untreated hypoglycemia in pregnancy can cause complications and may be fatal
• Lactation
  • There is no information available on presence in human or animal milk, effects on breastfed children, or on milk production
  • Dasiglucagon is a peptide and would be expected to be broken down to its constituent amino acids in infant's digestive tract, and is therefore unlikely to cause harm to an exposed infant